The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Abstract
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. In particular, the development of specific antibodies against the programmed death (PD-1) receptor, programmed death-ligand 1 (PD-L1), and the cytotoxic T-lymphocyte–associated protein 4 receptor in the therapeutic strategy of mNSCLC either in first- or in second-line settings have led to unprecedented prolonged survival for a proportion of these patients. Although clinical development of immune checkpoint inhibitors with anti–PD-1 and PD-L1 therapies largely began as monotherapy in the second-line setting, the more recent progress has shifted toward combination approaches in first-line settings as well as the integration of immunotherapy into the clinical paradigm in earlier stages. Today, with the exception of mNSCLC harboring targetable oncogenes, nearly all patients with mNSCLC receive PD-1 or PD-L1 therapy in first-line settings. Here we report the current status of first-line immunotherapy in mNSCLC together with current challenges in selecting the best immunotherapeutic approach for the individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationMok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citationLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Self-citationAtezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Yu, X., Harden, K., C Gonzalez, L., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., et al. (2009) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,491
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citationReck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Self-citationGadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
Self-citationEttinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Self-citationBorghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01605 · Cited by 656
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0237 · Cited by 623
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.028 · Cited by 599
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30365-9 · Cited by 483
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P. D., Goldschmidt, J., Novello, S., Orlandi, F., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.025 · Cited by 458
Taylor, M. H., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C. E., Wu, J., Stepan, D. E., Shumaker, R. C., & Motzer, R. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 435
Rodríguez-Abreu, D., Powell, S. F., Hochmair, M. J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S. Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.008 · Cited by 415
Self-citationWang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0366 · Cited by 396
Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.014 · Cited by 390
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz288 · Cited by 338
Self-citationHerbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Gervais, R., Perez-Gracia, J. L., Han, J.-Y., Majem, M., Forster, M. D., Monnet, I., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.001 · Cited by 320
Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.005 · Cited by 284
Boyer, M., Şendur, M. A. N., Rodríguez-Abreu, D., Park, K., Lee, D. H., Çiçin, I., Yumuk, P. F., Orlandi, F. J., Leal, T. A., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 247
Self-citationGarassino, M. C., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., Hochmair, M. J., Powell, S., Cheng, S. Y.-S., Bischoff, H. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30801-0 · Cited by 215
Self-citationMazieres, J., Rittmeyer, A., Gadgeel, S., Hida, T., Gandara, D. R., Cortinovis, D. L., Barlesi, F., Yu, W., Matheny, C., Ballinger, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.022 · Cited by 185
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Rapoport, B. L., & Anderson, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040959 · Cited by 164
Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9503 · Cited by 150
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
Suyama, K., & Iwase, H. (2018) · Cancer Control · doi:10.1177/1073274818789361 · Cited by 145
Gainor, J. F., Rizvi, H. A., Aguilar, E. J., Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M. J., Lydon, C. M., Illei, P. B., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.015 · Cited by 125
Self-citationPeters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 116
Self-citationWei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97
Garassino, M. C., Rodríguez‐Abreu, D., Gadgeel, S. M., Esteban, E., Felip, E., Speranza, G., Reck, M., Hui, R., Boyer, M. J., Cristescu, R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.427 · Cited by 94
Self-citationMazières, J., Kowalski, D. M., Luft, A. V., Vicente, D., Tafreshi, A., Gümüş, M., Лактионов, К. К., Hermes, B., Çiçin, İ., Rodríguez‐Cid, J. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01348 · Cited by 92
Reck, M., Wehler, T., Orlandi, F., Nogami, N., Barone, C., Moro‐Sibilot, D., Shtivelband, M. I., González-Larriba, J. L., Rothenstein, J. M., Früh, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03158 · Cited by 90
Self-citationGadgeel, S. M., Rodríguez‐Abreu, D., Felip, E., Esteban, E., Speranza, G., Reck, M., Hui, R., Boyer, M. J., Garon, E. B., Horinouchi, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz453.002 · Cited by 80
Self-citationPaz-Ares, L. G., Ciuleanu, T., Lee, J.-S., Urban, L., Caro, R. B., Park, K., Sakai, H., Ohe, Y., Nishio, M., Płużański, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9016 · Cited by 37
Self-citationGarassino, M. C., Gadgeel, S. M., Rodríguez‐Abreu, D., Felip, E., Esteban, E., Speranza, G., Hochmair, M. J., Powell, S. F., Garon, E. B., Hui, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9521 · Cited by 26
Self-citationFaehling, M., Kopp, M., Schwenk, B., Fallscheer, S., Kramberg, S., & Eckert, R. (2019) · Oncology · doi:10.1159/000500885 · Cited by 23
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
Reck, M., Mok, T. S. K., Socinski, M. A., Jotte, R. M., Lim, W., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1607 · Cited by 18
Self-citationWest, H., Cappuzzo, F., Reck, M., Mok, T. S. K., Jotte, R. M., Nishio, M., Kim, E., Morris, S., Shankar, G., Zou, W., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1579 · Cited by 18
Self-citationZhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G.-Q., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2289 · Cited by 17
Cited by
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Self-citationde Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Modulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
Metadata
- Authors
- Reck, M., Remon, J., & Hellmann, M. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-02-20
- Volume
- 40
- Issue
- 6
- Pages
- 586-597
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4205177974
- Cited by
- 842
- References
- 50
- FWCI
- 67.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.